nbsp;
Pruritis 1.4% of injections (9.2% of patients) 0.4% of injections (0.9% of patients)
Induration 0.4% of injections (2.5% of patients)
Ulceration 0.1% of injections (> 0.8% of patients)
Table 7 Summary of Possible or Probably Related Systemic Adverse Events Reported by > 2% of Patients treated with ELIGARD® 7.5 mg 7.5 mg 22.5 mg 30 mg 45 mg
In the patient populations studied with ELIGARD® 7.5 mg, a total of 86 hot flashes/sweats adverse events were reported in 70 patients. Of these, 71 events (83%) were mild; 14 (16%) were moderate; 1 (1%) was severe.
In the patient population studied with ELIGARD® 22.5 mg, a total of 84 hot flashes/sweats adverse events were reported in 66 patients. Of these, 73 events (87%) were mild; 11 (13%) were moderate; none were severe.
In the patient population studied with ELIGARD® 30 mg, a total of 75 hot flash adverse events were reported in 66 patients. Of these, 57 events (76%) were mild; 16 (21%) were moderate; 2 (3%) were severe.
In the patient population studied with ELIGARD® 45 mg, a total of 89 hot flash adverse events were reported in 64 patients. Of these, 62 events (70%) were mild; 27 (30%) were moderate; none were severe.
Study Number AGL9904 AGL9802 AGL9909 AGL0001 AGL0205
Number of patients 120 8 117 90 111
Treatment 1 injection every month up to 6 months 1 injection (surgically castrated patients) 1 injection every 3 months up to 6 months 1 injection every 4 months up to 8 months 1 injection every 6 months up to 12 months
Body System Adverse Event Number (Percent)
Body as a Whole Malaise and Fatigue 21 (17.5 %) 7 (6.0%) 12 (13.3%) 13 (11.7%)
Weakness 4 (3.6%)
Nervous System Dizziness 4 (3.3%) 4 (4.4%)
Vascular Hot flashes/sweats 68 (56.7%)Expected pharmacological consequences of testosterone suppression. 2 (25.0%) 66 (56.4%) 66 (73.3%) 64 (57.7%)
Renal/Urinary Urinary frequency 3 (2.6%) 2 (2.2%)
Nocturia 2 (2.2%)
Gastrointestinal Nausea 4 (3.4%) 2 (2.2%)
Gastroenteritis/colitis 3 (2.5%)
Skin Pruritis 3 (2.6%)
Clamminess 4 (4.4%)
Night sweats 3 (3.3%) 3 (2.7%)
Alopecia 2 (2.2%)
Musculoskeletal Arthralgia 4 (3.4%)
Myalgia 2 (2.2%) 5 (4.5%)
Pain in limb 3 (2.7%)
Reproductive Testicular atrophy 6 (5.0%) ·Anti Wrinkle ·Witchs Brew Antibacterial Hand
About us - Contact us - TOP ↑
In the patient population studied with ELIGARD® 22.5 mg, a total of 84 hot flashes/sweats adverse events were reported in 66 patients. Of these, 73 events (87%) were mild; 11 (13%) were moderate; none were severe.
In the patient population studied with ELIGARD® 30 mg, a total of 75 hot flash adverse events were reported in 66 patients. Of these, 57 events (76%) were mild; 16 (21%) were moderate; 2 (3%) were severe.
In the patient population studied with ELIGARD® 45 mg, a total of 89 hot flash adverse events were reported in 64 patients. Of these, 62 events (70%) were mild; 27 (30%) were moderate; none were severe.
